复方苦参注射液联合同步放化疗治疗宫颈鳞癌术后患者的临床研究

Clinical Study of Compound Kushen Injection Combined with Concurrent Chemoradiotherapy in the Treatment of Postoperative Patients with Cervical Squamous Cell Carcinoma

目的:探讨宫颈鳞癌患者经根治性子宫切除术后给予复方苦参注射液联合同步放化疗方案的治疗效果。方法:选取2018年12月~2023年10月期间某院收治的80例宫颈鳞癌患者作为研究对象,根据治疗方案不同分为对照组和观察组,每组40例。两组患者均进行根治性子宫切除术,术后对照组患者给予同步放化疗方案治疗,观察组患者在对照组治疗基础上加用复方苦参注射液,两组均治疗42天。比较两组患者肿瘤标记物[鳞状上皮细胞癌相关抗原(SCC-Ag)]、炎症因子[肿瘤坏死因子-α(TNF-α)和白介素-2(IL-2)]、免疫指标[自然杀伤(NK)细胞]及不良反应发生情况。结果:治疗后,观察组患者血清SCC-Ag、TNF-α和IL-2水平均低于对照组,NK细胞水平高于对照组(P<0.05)。治疗期间,观察组患者胃肠道反应发生率低于对照组(P<0.05)。结论:复方苦参注射液联合同步放化疗治疗可抑制宫颈鳞癌术后患者肿瘤生长,降低SCC-Ag、炎症因子水平,提高NK细胞水平,且减少胃肠道不良反应的发生。

Objective:To investigate the therapeutic effect of compound Kushen injection combined with concurrent chemoradiotherapy in patients with cervical squamous cell carcinoma after radical hysterectomy.Methods:A total of 80 patients with cervical squamous cell carcinoma who were admitted to a hospital from December 2018 to October 2023 were selected and divided into the control group and the observation group according to different treatment plans,with 40 patients in each group.Both groups underwent radical hysterectomy.Following surgery,the control group received concurrent chemoradiotherapy,and the observation group received compound Kushen injection in addition to the treatment received by the control group,and both groups were treated for 42 days.Tumor markers(squamous cell carcinoma antigen[SCC-Ag]),inflammatory factors[tumor necrosis factor-α(TNF-α)and interleukin-2(IL-2)],immune indicators[natural killer(NK)cell]and the incidence of adverse reactions were compared between the two groups.Results:Following treatment,the serum levels of SCC-Ag,TNF-αand IL-2 in the observation group were lower than those in the control group and the NK cell level was higher than that in the control group(P<0.05).During the treatment period,the incidence of gastrointestinal reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Compound Kushen injection combined with concurrent chemoradiotherapy can effectively inhibit tumor growth,decrease SCC-Ag and inflammatory factors levels,elevate NK cell levels,and reduce the occurrence of gastrointestinal adverse reactions.